- Home
- ANGX vs LCTX Comparison
ANGX vs LCTX Comparison
Compare ANGX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | LCTX |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | 311 | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 445.1M | 388.6M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ANGX | LCTX |
|---|---|---|
| Price | $2.57 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $9.75 | $6.25 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | $46.23 | $109.40 |
| Revenue Next Year | $25.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $2.05 | $0.48 |
| 52 Week High | $18.90 | $2.09 |
Technical Indicators
Market Signals| Indicator | ANGX | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 29.25 |
| Support Level | $2.16 | $1.14 |
| Resistance Level | $2.83 | $1.31 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 7.10 | 2.86 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.